Jeremy A. Squire

List of Publications by Year
in descending order

386 papers	38,095 citations	6124 83 h-index	3844 184 g-index
395 all docs	395 docs citations	395 times ranked	42490 citing authors

#	Article	IF	Citations
1	Genetic aspects of primary bone tumors. , 2022, , 531-542.		0
2	High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts. Modern Pathology, 2021, 34, 478-489.	2.9	13
3	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. Expert Review of Molecular Diagnostics, 2021, 21, 161-173.	1.5	2
4	The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 9550.	1.8	15
5	Epithelialâ€“Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics. Genes, 2021, 12, 1900.	1.0	22
6	The Dual Role of Serotonin in Colorectal Cancer. Trends in Endocrinology and Metabolism, 2020, 31, 611-625.	3.1	39
7	Contributions of HOX genes to cancer hallmarks: Enrichment pathway analysis and review. Tumor Biology, 2020, 42, 101042832091805.	0.8	35
8	Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). Journal of the National Cancer Institute, 2020, 112, 1098-1104.	3.0	21
9	Emerging role of PTEN loss in evasion of the immune response to tumours. British Journal of Cancer, 2020, 122, 1732-1743.	2.9	95
10	Partial Monosomy 4p and Trisomy 12q due to a t(4;12)(p16.3;q24.31) Familial Translocation in Two Cousins. Molecular Syndromology, 2019, 10, 264-271.	0.3	0
11	PTENâ€deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. Prostate, 2019, 79, 969-979.	1.2	58
12	Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesis. Journal of Pathology, 2019, 249, 102-113.	2.1	26
13	Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice. , 2019, , 149-162.		0
14	MP28-02â€ƒQUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER. Journal of Urology, 2019, 201, .	0.2	0
15	Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology, 2018, 15, 222-234.	1.9	408
16	Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections. Laboratory Investigation, 2018, 98, 403-413.	1.7	10
17	Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome. International Journal of Gynecological Cancer, 2018, 28, 459-465.	1.2	25
18	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	0.6	14

#	Article	IF	Citations
19	Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer. Molecular Cytogenetics, 2018, 11, 1.	0.4	29
20	Centrosome amplification in chondrosarcomas: A primary cell culture and cryopreserved tumor sample study. Oncology Letters, 2017, 13, 1835-1835.	0.8	1
21	Complex Mosaic Ring Chromosome 11 Associated with Hemizygous Loss of 8.6 Mb of 11q24.2qter in Atypical Jacobsen Syndrome. Molecular Syndromology, 2017, 8, 45-49.	0.3	3
22	Molecular characterization of short-term primary cultures and comparison with corresponding tumor tissue of Brazilian glioblastoma patients. Translational Cancer Research, 2017, 6, 332-345.	0.4	7
23	Extracellular Vesicles: Evolving Factors in Stem Cell Biology. Stem Cells International, 2016, 2016, 1-17.	1.2	179
24	Lacrimal gland anaplastic kinaseâ€“positive large Bâ€cell lymphoma (LBCLâ€ALK+) with an atypical clinical presentation. Clinical and Experimental Ophthalmology, 2016, 44, 520-522.	1.3	2
25	STAT1â€associated intratumoural T_H1 immunity predicts chemotherapy resistance in highâ€grade serous ovarian cancer. Journal of Pathology: Clinical Research, 2016, 2, 259-270.	1.3	42
26	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Modern Pathology, 2016, 29, 904-914.	2.9	71
27	First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16. Gynecologic Oncology, 2016, 140, 486-493.	0.6	3
28	In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 607-617.	1.4	32
29	Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery. Expert Review of Proteomics, 2016, 13, 395-409.	1.3	60
30	Abstract 716: STAT1 expression in the tumor-stroma microenvironment is influenced by loss of PTEN in prostate cancer. , 2016, , .		0
31	Abstract 441: Association of interferon inducible genes with tumor immune microenvironment and chemotherapy resistance in high-grade serous epithelial ovarian cancer. , 2016, , .		0
32	MP1-17 PTEN STATUS DETERMINATION IN PROSTATE CANCER: COMPARISON OF IHC AND FISH IN A LARGE MULTI-CENTER COHORT. Journal of Urology, 2015, 193, .	0.2	0
33	A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investigational New Drugs, 2015, 33, 969-976.	1.2	50
34	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	1.2	55
35	Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 851-856.	3.3	321
36	Genetic aspects of bone tumors. , 2015, , 305-318.		0

#	Article	IF	Citations
37	Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1270-4.	0.6	77
38	ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clinical Cancer Research, 2015, 21, 2569-2579.	3.2	60
39	A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. British Journal of Cancer, 2015, 112, 1215-1222.	2.9	54
40	Composite Mantle Cell and Primary Cutaneous Anaplastic Large Cell Lymphoma. American Journal of Dermatopathology, 2015, 37, 232-236.	0.3	9
41	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology, 2015, 28, 128-137.	2.9	136
42	Current state of biomarkers in ovarian cancer prognosis. Future Oncology, 2015, 11, 3187-3195.	1.1	45
43	Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice. , 2015, , 159-175.		0
44	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532.	5.1	291
45	Smoking-induced chromosomal segregation anomalies identified by FISH analysis of sperm. Molecular Cytogenetics, 2014, 7, 58.	0.4	17
46	Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. Cancer Genetics, 2014, 207, 474-488.	0.2	76
47	SINGLE CELL DERIVED CLONAL ANALYSIS OF HUMAN GLIOBLASTOMA LINKS FUNCTIONAL AND GENOMIC HETEROGENEITY. Neuro-Oncology, 2014, 16, iii14-iii14.	0.6	1
48	MP79-14 FISH ANALYSIS OF 637 PROSTATE CANCERS: ASSOCIATION OF PTEN GENOMIC DELETION WITH EARLIER ONSET OF DISEASE PROGRESSION AND WORSE PROGNOSIS. Journal of Urology, 2014, 191, .	0.2	0
49	Association of PTEN protein loss with upgrading of prostate cancer from biopsy to radical prostatectomy.. Journal of Clinical Oncology, 2014, 32, 127-127.	0.8	2
50	Digital Expression Profiling Identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as Potential Predictive Biomarkers for Neo-Adjuvant Chemotherapy Response in Paediatric Osteosarcoma. PLoS ONE, 2014, 9, e95843.	1.1	49
51	Abstract 1106: The tumor immune microenvironment modulates response to chemotherapy in high-grade serous epithelial ovarian cancer. , 2014, , .		0
52	Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet Journal of Rare Diseases, 2013, 8, 33.	1.2	38
53	Identification of the IGF1/PI3K/NF ÎºB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer, 2013, 13, 549.	1.1	95
54	Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecologic Oncology, 2013, 130, 269-274.	0.6	91

#	Article	IF	Citations
55	PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Modern Pathology, 2013, 26, 435-447.	2.9	73
56	Copy Number and Expression Alterations of miRNAs in the Ovarian Cancer Cell Line OVCAR-3: Impact on Kallikrein 6 Protein Expression. Clinical Chemistry, 2013, 59, 296-305.	1.5	15
57	Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems. Neoplasia, 2013, 15, 939-IN27.	2.3	31
58	Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. Cancer Genetics, 2013, 206, 103-115.	0.2	9
59	2136 APPLICATION OF FOUR COLOR FLUORESCENCE IN SITU HYBRIDIZATION IDENTIFIES GENOMIC DELETIONS OF THE PTEN GENE IN 384 OF 2115 (18.2%) DIAGNOSTIC PROSTATE CANCER-POSITIVE NEEDLE CORES. Journal of Urology, 2013, 189, .	0.2	0
60	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2013, 15, 415-453.	1.2	397
61	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2013, 137, 828-860.	1.2	415
62	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 2013, 8, 823-859.	0.5	792
63	TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. Clinical Cancer Research, 2013, 19, 5202-5209.	3.2	39
64	MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma. Journal of Biological Chemistry, 2013, 288, 21307-21319.	1.6	95
65	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology: Erratum. Journal of Thoracic Oncology, 2013, 8, 1343.	0.5	17
66	The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2013, 31, 11085-11085.	0.8	1
67	Phase II study of PX-866 in recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2053-2053.	0.8	3
68	Abstract A53: Biomarkers of chemotherapy resistance in serous epithelial ovarian cancer identified by integrative genomic and transcriptomic analysis. , 2013, , .		0
69	NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy. Clinical Cancer Research, 2012, 18, 308-316.	3.2	43
70	The Genetics of Osteosarcoma. Sarcoma, 2012, 2012, 1-11.	0.7	193
71	Automated Quantitative Analysis of p53, Cyclin D1, Ki67 and pERK Expression in Breast Carcinoma Does Not Differ from Expert Pathologist Scoring and Correlates with Clinico-Pathological Characteristics. Cancers, 2012, 4, 725-742.	1.7	16
72	Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 1513-1521.	0.5	46

#	Article	IF	Citations
73	Caspase-8 is essential for maintaining chromosomal stability and suppressing B-cell lymphomagenesis. Blood, 2012, 119, 3495-3502.	0.6	15
74	The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Translational Oncology, 2012, 5, 453-460.	1.7	33
75	Maternal gametic transmission of translocations or inversions of human chromosome 11p15.5 results in regional DNA hypermethylation and downregulation of CDKN1C expression. Genomics, 2012, 99, 25-35.	1.3	18
76	Multilevel Whole-Genome Analysis Reveals Candidate Biomarkers in Clear Cell Renal Cell Carcinoma. Cancer Research, 2012, 72, 5273-5284.	0.4	83
77	Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor. Cancer Genetics, 2012, 205, 220-231.	0.2	25
78	EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer, 2012, 12, 91.	1.1	325
79	Karyotype/phenotype correlation in partial trisomies of the long arm of chromosome 16: Case report and review of literature. American Journal of Medical Genetics, Part A, 2012, 158A, 821-827.	0.7	12
80	Copy number alterations of câ€MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer, 2012, 118, 4053-4062.	2.0	105
81	A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 67-78.	1.4	11
82	Interactions and relationships of PTEN, ERG, SPINK1 and AR in castrationâ€resistant prostate cancer. Histopathology, 2012, 60, 645-652.	1.6	52
83	PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes and Cancer, 2012, 51, 149-160.	1.5	53
84	TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 11-11.	0.8	0
85	Abstract 3004: Biomarker identification through integrative bioinformatics analysis of serous epithelial ovarian cancer tumor samples. , 2012, , .		0
86	Abstract 2999: Gene expression signature of differential response to chemotherapy in sporadic pediatric osteosarcoma. , 2012, , .		0
87	Phase II study of PX-866 in recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2051-2051.	0.8	0
88	A Radically Different Mechanism for S -Adenosylmethionineâ€“Dependent Methyltransferases. Science, 2011, 332, 604-607.	6.0	230
89	Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma. Journal of Molecular Diagnostics, 2011, 13, 289-296.	1.2	49
90	133 EVALUATION OF PTEN AND TMPRSS2-ERG ABNORMALITIES IN PROSTATE CANCER BY FISH AND IMMUNOHISTOCHEMISTRY TO ADDRESS INTRA- AND INTER- TISSUE HETEROGENEITY AND DISEASE PROGRESSION. Journal of Urology, 2011, 185, .	0.2	0

#	Article	IF	Citations
91	1607 HIGH-RESOLUTION DETECTION OF PTEN GENOMIC DELETION BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH) USING 330 FIXED PARAFFIN-EMBEDDED TISSUE SAMPLES. Journal of Urology, 2011, 185, .	0.2	0
92	Genomic instability and copyâ€number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. Molecular Oncology, 2011, 5, 48-60.	2.1	21
93	Cfr and RlmN Contain a Single [4Fe-4S] Cluster, which Directs Two Distinct Reactivities for S-Adenosylmethionine: Methyl Transfer by S_N2 Displacement and Radical Generation. Journal of the American Chemical Society, 2011, 133, 19586-19589.	6.6	60
94	Prostate Cancer as a Model System for Genetic Diversity in Tumors. Advances in Cancer Research, 2011, 112, 183-216.	1.9	28
95	Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genetics, 2011, 204, 138-146.	0.2	126
96	Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genetics, 2011, 204, 525-535.	0.2	49
97	The Role of RUNX2 in Osteosarcoma Oncogenesis. Sarcoma, 2011, 2011, 1-13.	0.7	118
98	PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU International, 2011, 107, 477-485.	1.3	99
99	PTEN deletion and heme oxygenaseâ€1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. Journal of Pathology, 2011, 224, 90-100.	2.1	62
100	Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. Prostate, 2011, 71, 778-790.	1.2	21
101	The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer, 2011, 117, 290-300.	2.0	48
102	Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Annals of Oncology, 2011, 22, 2403-2410.	0.6	40
103	Integrated Cytogenetic and High-Resolution Array CGH Analysis of Genomic Alterations Associated with <i>MYCN</i> Amplification. Cytogenetic and Genome Research, 2011, 134, 27-39.	0.6	8
104	Detection of*ERG*gene rearrangements and*PTEN*deletions in unsuspected prostate cancer of the transition zone. Cancer Biology and Therapy, 2011, 11, 562-566.	1.5	35
105	Role of Pirh2 in Mediating the Regulation of p53 and c-Myc. PLoS Genetics, 2011, 7, e1002360.	1.5	65
106	Abstract 320: Association of higher Gleason grade with presence of PTEN deletion in prostatic adenocarcinoma. , 2011, , .		0
107	Abstract 3207: Automated quantitative analysis of p53, cyclin D1 and pErk expression in breast carcinoma does not differ from expert pathologist scoring and correlates well with clinico-pathological characteristics. , 2011, , .		0
108	Abstract 317: 1q32.1 and 16q21 genomic alterations implicate KIF14/MDM4/PIK3C2ÃŸ and CDH11 as independent prognostic markers of relapse in localized Ewing Family of Tumors. , 2011, , .		0

#	Article	IF	Citations
109	Abstract 1168: Integrated genomic, microRNA (miRNA) and proteomic profiling by stable isotope labeling with amino acids in cell culture (SILAC) of ovarian carcinoma for biomarker discovery. , 2011, , .		0
110	Abstract 1719: Integrative genomic analysis of ovarian cancer cell lines points to EMT involvement in the development of cisplatin resistance. , 2011, , .		0
111	Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer, 2010, 10, 202.	1.1	115
112	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116, 5599-5607.	2.0	143
113	A rare case of trisomy 15pterâ€q21.2 due to a de novo marker chromosome. American Journal of Medical Genetics, Part A, 2010, 152A, 753-758.	0.7	7
114	Development of metastatic and nonâ€metastatic tumor lines from a patient's prostate cancer specimenâ€"identification of a small subpopulation with metastatic potential in the primary tumor. Prostate, 2010, 70, 1636-1644.	1.2	31
115	Genomic alterations detected by comparative genomic hybridization in ovarian endometriomas. Brazilian Journal of Medical and Biological Research, 2010, 43, 799-805.	0.7	18
116	Genetic Aspects of Bone Tumors. , 2010, , 161-170.		1
117	Plk4 is required for cytokinesis and maintenance of chromosomal stability. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6888-6893.	3.3	91
118	Analysis of Segmental Duplications, Mouse Genome Synteny and Recurrent Cancer-Associated Amplicons in Human Chromosome 6p21â€"p12. Cytogenetic and Genome Research, 2010, 128, 199-213.	0.6	16
119	FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. Journal of Clinical Pathology, 2010, 63, 630-634.	1.0	83
120	Prognostic impact of adenomatous polyposis coli gene expression in osteosarcoma of the extremities. European Journal of Cancer, 2010, 46, 3307-3315.	1.3	7
121	Cytogenetic molecular delineation of a terminal 18q deletion suggesting neo-telomere formation. European Journal of Medical Genetics, 2010, 53, 404-407.	0.7	5
122	Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. Journal of Clinical Investigation, 2010, 120, 3310-3325.	3.9	89
123	Abstract 3037: Integrated Genomic, MicroRNA (miRNA) and Proteomic Profiling of Ovarian Carcinoma for Biomarker Discovery. , 2010, , .		0
124	Abstract 2136: Combined 8q gain and 10q loss predicts for relapse following radical radiotherapy in intermediate risk prostate cancer. , 2010, , .		0
125	Abstract 326: Prognostic value of KIF14 and MDM4 in Ewing's sarcoma. , 2010, , .		0
126	Abstract 3404: Identification of potential oncogenes in osteosarcoma pathogenesis by high-resolution array comparative genomic hybridization. , 2010, , .		0

#	Article	IF	Citations
127	Abstract 320: Fine structure genomic mapping of chromosome 10q23 interstitial deletions in prostate cancer reveals thePTENgene locus as the minimum region deleted. , 2010, , .		0
128	The interval between Ins2 and Ascl2 is dispensable for imprinting centre function in the murine Beckwithâ€“Wiedemann region. Human Molecular Genetics, 2009, 18, 4255-4267.	1.4	12
129	Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CICâ€“DUX4 fusion gene event. Cancer Genetics and Cytogenetics, 2009, 195, 1-11.	1.0	95
130	Reduced tumorigenesis in p53 knockout mice exposed in utero to lowâ€dose vitamin E. Cancer, 2009, 115, 1563-1575.	2.0	10
131	PTEN genomic deletion is associated with pâ€Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. Journal of Pathology, 2009, 218, 505-513.	2.1	196
132	Highâ€resolution array CGH identifies novel regions of genomic alteration in intermediateâ€risk prostate cancer. Prostate, 2009, 69, 1091-1100.	1.2	75
133	TMPRSS2-ERG and PTEN loss in prostate cancer. Nature Genetics, 2009, 41, 509-510.	9.4	69
134	Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens. Cell Stem Cell, 2009, 4, 568-580.	5.2	881
135	Direct Profiling of Cancer Biomarkers in Tumor Tissue Using a Multiplexed Nanostructured Microelectrode Integrated Circuit. ACS Nano, 2009, 3, 3207-3213.	7.3	82
136	Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Human Molecular Genetics, 2009, 18, 1962-1975.	1.4	119
137	Phase II Study of Preoperative Gefitinib in Clinical Stage I Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6229-6236.	0.8	93
138	Recurrent RECQL4 Imbalance and Increased Gene Expression Levels Are Associated with Structural Chromosomal Instability in Sporadic Osteosarcoma. Neoplasia, 2009, 11, 260-IN6.	2.3	57
139	Offâ€gas treatment carbon footprint calculator: Form and function. Remediation, 2008, 19, 39-51.	1.1	4
140	Sustainable soil remediation by refrigerated condensation at sites with â€œhigh-concentrationâ€• recalcitrant compounds and NAPL: Two case studies. , 2008, 19, 53-72.		3
141	High definition cytogenetics and oligonucleotide aCGH analyses of cisplatinâ€resistant ovarian cancer cells. Genes Chromosomes and Cancer, 2008, 47, 427-436.	1.5	15
142	Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern Pathology, 2008, 21, 1451-1460.	2.9	254
143	Prostatic preneoplasia and beyond. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 156-181.	3.3	23
144	Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversionâ€“insertion mechanism of EWSâ€“ERG fusion gene formation: a case analysis and literature review. Cancer Genetics and Cytogenetics, 2008, 181, 81-92.	1.0	38

#	Article	IF	Citations
145	In Vitro Analysis of Integrated Global High-Resolution DNA Methylation Profiling with Genomic Imbalance and Gene Expression in Osteosarcoma. PLoS ONE, 2008, 3, e2834.	1.1	71
146	Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. Molecular Oncology, 2008, 2, 250-260.	2.1	16
147	Decitabine-Induced Demethylation of 5â€² CpG Island in GADD45A Leads to Apoptosis in Osteosarcoma Cells. Neoplasia, 2008, 10, 471-480.	2.3	54
148	Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008, 26, 4268-4275.	0.8	674
149	TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes and Development, 2008, 22, 2677-2691.	2.7	378
150	Distinct Patterns of Structural and Numerical Chromosomal Instability Characterize Sporadic Ovarian Cancer. Neoplasia, 2008, 10, 1057-IN3.	2.3	40
151	Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenetic and Genome Research, 2008, 122, 5-15.	0.6	72
152	Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Human Molecular Genetics, 2008, 17, 1363-1372.	1.4	289
153	Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer. Current Genomics, 2008, 9, 394-408.	0.7	227
154	ASAP1, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis. Cancer Research, 2008, 68, 4352-4359.	0.4	87
155	Epigenetic and Phenotypic Consequences of a Truncation Disrupting the Imprinted Domain on Distal Mouse Chromosome 7. Molecular and Cellular Biology, 2008, 28, 1092-1103.	1.1	14
156	Fluorescence In Situ Hybridization. Springer Protocols, 2008, , 239-255.	0.1	2
157	Murine Pif1 Interacts with Telomerase and Is Dispensable for Telomere Function In Vivo. Molecular and Cellular Biology, 2007, 27, 1017-1026.	1.1	64
158	Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. Journal of Clinical Oncology, 2007, 25, 2184-2190.	0.8	92
159	Chromosome 6p amplification and cancer progression. Journal of Clinical Pathology, 2007, 60, 1-7.	1.0	89
160	Correlating breakage-fusion-bridge events with the overall chromosomal instability and in vitro karyotype evolution in prostate cancer. Cytogenetic and Genome Research, 2007, 116, 1-11.	0.6	48
161	Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. International Journal of Oncology, 2007, , .	1.4	20
162	Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Letters, 2007, 250, 284-291.	3.2	48

#	Article	IF	Citations
163	Application and interpretation of FISH in biomarker studies. Cancer Letters, 2007, 249, 97-109.	3.2	27
164	Genomic Alterations in Sporadic Synchronous Primary Breast Cancer Using Array and Metaphase Comparative Genomic Hybridization. Neoplasia, 2007, 9, 511-520.	2.3	28
165	Telomere Attrition in Isolated High-Grade Prostatic Intraepithelial Neoplasia and Surrounding Stroma Is Predictive of Prostate Cancer. Neoplasia, 2007, 9, 81-89.	2.3	44
166	Identification ofPFTAIREprotein kinase 1, a novel cell division cycle-2 related gene, in the motile phenotype of hepatocellular carcinoma cells. Hepatology, 2007, 46, 436-445.	3.6	46
167	Profiling genomic copy number changes in retinoblastoma beyond loss ofRB1. Genes Chromosomes and Cancer, 2007, 46, 118-129.	1.5	92
168	Microdeletion and concurrent translocation associated with a complexTMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes and Cancer, 2007, 46, 861-863.	1.5	14
169	Expression of major vault protein gene in osteosarcoma patients. Journal of Orthopaedic Research, 2007, 25, 958-963.	1.2	12
170	Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation. Cancer Cell International, 2007, 7, 14.	1.8	48
171	FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. British Journal of Cancer, 2007, 97, 678-685.	2.9	260
172	Characterization of trisomy 8 in pediatric undifferentiated sarcomas using advanced molecular cytogenetic techniques. Cancer Genetics and Cytogenetics, 2007, 174, 35-41.	1.0	20
173	Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2007, 179, 52-61.	1.0	40
174	Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses. Cancer Genetics and Cytogenetics, 2007, 179, 102-111.	1.0	20
175	Stem cell enrichment approaches. Seminars in Cancer Biology, 2007, 17, 257-264.	4.3	20
176	Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Seminars in Cancer Biology, 2007, 17, 5-18.	4.3	114
177	Molecular characterization of deletion breakpoints in adults with 22q11 deletion syndrome. Human Genetics, 2007, 120, 837-845.	1.8	48
178	Cytogenetically balanced translocations are associated with focal copy number alterations. Human Genetics, 2007, 120, 795-805.	1.8	44
179	Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. International Journal of Oncology, 2007, 30, 5-17.	1.4	66
180	The Role of Telomere Maintenance in the Spontaneous Growth Arrest of Pediatric Low-Grade Gliomas. Neoplasia, 2006, 8, 136-142.	2.3	72

#	Article	IF	Citations
181	Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with Rearrangement. Neoplasia, 2006, 8, 465-469.	2.3	165
182	Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. British Journal of Cancer, 2006, 94, 1452-1459.	2.9	95
183	Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Modern Pathology, 2006, 19, 1546-1554.	2.9	42
184	The breakageâ€“fusionâ€“bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma. Chromosoma, 2006, 115, 459-467.	1.0	46
185	Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genetics and Cytogenetics, 2006, 169, 128-137.	1.0	151
186	Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America. Cancer Genetics and Cytogenetics, 2006, 170, 40-47.	1.0	11
187	Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer, 2006, 6, 237.	1.1	95
188	Large scale copy number variation (CNV) at 14q12 is associated with the presence of genomic abnormalities in neoplasia. BMC Genomics, 2006, 7, 138.	1.2	24
189	The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression. BMC Genomics, 2006, 7, 65.	1.2	27
190	Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro. Genes Chromosomes and Cancer, 2006, 45, 136-146.	1.5	15
191	Hydrocephaly, penoscrotal transposition, and digital anomalies associated with de novo pseudodicentric rearranged chromosome 13 characterized by classical cytogenetic methods and mBAND analysis. American Journal of Medical Genetics, Part A, 2006, 140A, 1321-1325.	0.7	8
192	Constitutional UPD for chromosome 11p15 in individuals with isolated hemihyperplasia is associated with high tumor risk and occurs following assisted reproductive technologies. American Journal of Medical Genetics, Part A, 2006, 140A, 1497-1503.	0.7	69
193	A role for Brca1 in chromosome end maintenance. Human Molecular Genetics, 2006, 15, 831-838.	1.4	70
194	Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour. Journal of Clinical Pathology, 2006, 60, 426-428.	1.0	31
195	Establishment in Severe Combined Immunodeficiency Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progressionâ€“Related Changes. Clinical Cancer Research, 2006, 12, 4043-4054.	3.2	102
196	Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16930-16935.	3.3	32
197	Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurgical Focus, 2005, 19, 1-17.	1.0	83
198	Acute monocytic leukemia and multiple abnormalities in a child with duplication of 1q detected by GTG-banding and SKY. Leukemia Research, 2005, 29, 1465-1467.	0.4	3

#	Article	IF	Citations
199	Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. Laboratory Investigation, 2005, 85, 664-674.	1.7	36
200	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Laboratory Investigation, 2005, 85, 1392-1404.	1.7	107
201	The use of whole genome amplification in the study of human disease. Progress in Biophysics and Molecular Biology, 2005, 88, 173-189.	1.4	80
202	A method for accurate detection of genomic microdeletions using real-time quantitative PCR. BMC Genomics, 2005, 6, 180.	1.2	89
203	An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes and Cancer, 2005, 42, 392-403.	1.5	50
204	Transcriptional profiling on chromosome 19p indicated frequent downregulation ofACP5 expression in hepatocellular carcinoma. International Journal of Cancer, 2005, 114, 902-908.	2.3	16
205	DNA methylation in the CTCF-binding site I and the expression pattern of theH19 gene: Does positive expression predict poor prognosis in early stage head and neck carcinomas?. Molecular Carcinogenesis, 2005, 44, 102-110.	1.3	24
206	HER2 Amplification and Overexpression Is Not Present in Pediatric Osteosarcoma: A Tissue Microarray Study. Pediatric and Developmental Pathology, 2005, 8, 525-532.	0.5	43
207	Molecular cytogenetic analysis in the study of brain tumors: findings and applications. Neurosurgical Focus, 2005, 19, 1-36.	1.0	25
208	Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16415-16420.	3.3	57
209	Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. International Journal of Oncology, 2005, 27, 1029.	1.4	26
210	Erlotinib in Lung Cancer â€" Molecular and Clinical Predictors of Outcome. New England Journal of Medicine, 2005, 353, 133-144.	13.9	1,787
211	High-Resolution Mapping of Genomic Imbalance and Identification of Gene Expression Profiles Associated with Differential Chemotherapy Response in Serous Epithelial Ovarian Cancer. Neoplasia, 2005, 7, 603-IN20.	2.3	81
212	Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients. Clinical Cancer Research, 2005, 11, 621-31.	3.2	15
213	Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. Clinical Cancer Research, 2005, 11, 1319-26.	3.2	22
214	Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. International Journal of Oncology, 2005, 27, 1029-37.	1.4	29
215	Comparative genomic hybridization analysis of pediatric adamantinomatous craniopharyngiomas and a review of the literature. Journal of Neurosurgery: Pediatrics, 2004, 101, 85-90.	0.8	9
216	High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenetic and Genome Research, 2004, 107, 77-82.	0.6	39

#	Article	IF	Citations
217	Collaboration of Brca1 and Chk2 in tumorigenesis. Genes and Development, 2004, 18, 1144-1153.	2.7	61
218	Use of whole genome amplification and comparative genomic hybridisation to detect chromosomal copy number alterations in cell line material and tumour tissue. Cytogenetic and Genome Research, 2004, 105, 18-24.	0.6	23
219	Defective DNA Strand Break Repair after DNA Damage in Prostate Cancer Cells. Cancer Research, 2004, 64, 8526-8533.	0.4	108
220	Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO Journal, 2004, 23, 3677-3688.	3.5	179
221	Identification of human brain tumour initiating cells. Nature, 2004, 432, 396-401.	13.7	6,758
222	Combined spectral karyotyping, multicolor banding, and microarray comparative genomic hybridization analysis provides a detailed characterization of complex structural chromosomal rearrangements associated with gene amplification in the osteosarcoma cell line MG-63. Cancer Genetics and Cytogenetics, 2004, 153, 158-164.	1.0	35
223	Evolution of 8p loss in transformed human prostate epithelial cells. Cancer Genetics and Cytogenetics, 2004, 154, 36-43.	1.0	17
224	Traditional Banding of Chromosomes for Cytogenetic Analysis. Current Protocols in Cell Biology, 2004, 23, Unit 22.3.	2.3	16
225	Preparation of Cytogenetic Specimens from Tissue Samples. Current Protocols in Cell Biology, 2004, 23, Unit 22.2.	2.3	15
226	Overview of Cytogenetic Chromosome Analysis. Current Protocols in Cell Biology, 2004, 23, Unit 22.1.	2.3	1
227	Comparative Genomic Hybridization. Current Protocols in Cell Biology, 2004, 25, Unit 22.6.	2.3	7
228	Sister Chromatid Exchange. Current Protocols in Cell Biology, 2004, 25, Unit 22.7.	2.3	15
229	Detection of Mitotic Figures and Components of the Mitotic Machinery. Current Protocols in Cell Biology, 2004, 25, Unit 22.8.	2.3	0
230	Multi-Color FISH Techniques. , 2004, Chapter 22, Unit 22.5.		18
231	Fluorescence In Situ Hybridization (FISH). Current Protocols in Cell Biology, 2004, 23, Unit 22.4.	2.3	55
232	The use of cytogenetics in understanding ovarian cancer. Biomedicine and Pharmacotherapy, 2004, 58, 17-23.	2.5	16
233	Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction. American Journal of Pathology, 2004, 164, 285-293.	1.9	47
234	Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes. International Journal of Oncology, 2004, 25, 1357-64.	1.4	2

#	Article	IF	Citations
235	The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell, 2003, 3, 37-50.	7.7	73
236	Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genetics and Cytogenetics, 2003, 144, 91-99.	1.0	75
237	Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes and Cancer, 2003, 36, 7-16.	1.5	109
238	High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes and Cancer, 2003, 38, 215-225.	1.5	149
239	Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model. International Journal of Cancer, 2003, 104, 36-43.	2.3	58
240	De novo 1q32q44 duplication and distal 1q trisomy syndrome. American Journal of Medical Genetics Part A, 2003, 120A, 229-233.	2.4	29
241	Quantitative PCR identifies a minimal deleted region of 120â€‰kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia, 2003, 17, 1313-1323.	3.3	33
242	Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene, 2003, 22, 1978-1987.	2.6	76
243	Chromosomal Localization of DNA Amplifications in Neuroblastoma Tumors Using cDNA Microarray Comparative Genomic Hybridization. Neoplasia, 2003, 5, 53-62.	2.3	101
244	Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood. Lancet, The, 2003, 362, 1112-1119.	6.3	53
245	Transcriptional profiling of medulloblastoma in children. Journal of Neurosurgery, 2003, 99, 534-541.	0.9	36
246	Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Human Molecular Genetics, 2003, 12, 61R-68.	1.4	249
247	Advanced Cancer Genetics in Neurosurgical Research. Neurosurgery, 2003, 53, 1168-1178.	0.6	2
248	Chromosomal imbalances detected in primary bone tumors by comparative genomic hybridization and interphase fluorescence in situ hybridization. Genetics and Molecular Biology, 2003, 26, 107-113.	0.6	1
249	Identification of a cancer stem cell in human brain tumors. Cancer Research, 2003, 63, 5821-8.	0.4	3,675
250	Prognostic impact of chromosomal aberrations in Ewing tumours. British Journal of Cancer, 2002, 86, 1763-1769.	2.9	89
251	Microarray CGH. , 2002, 204, 191-208.		16
252	Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith-Wiedemann syndrome. Human Molecular Genetics, 2002, 11, 1317-1325.	1.4	322

#	Article	IF	Citations
253	Morphological and cytogenetic analysis of human giant oocytes and giant embryos. Human Reproduction, 2002, 17, 2394-2401.	0.4	96
254	Renal Abnormalities in Beckwith-Wiedemann Syndrome Are Associated with 11p15.5 Uniparental Disomy. Journal of the American Society of Nephrology: JASN, 2002, 13, 2077-2084.	3.0	62
255	2 Comparative genomic hybridization analysis using metaphase or microarray slides. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, 2, 11-21.	0.0	0
256	Spectral Karyotyping. , 2002, 204, 85-104.		7
257	Applications of SKY in Cancer Cytogenetics. Cancer Investigation, 2002, 20, 373-386.	0.6	60
258	Application of Microarrays to the Analysis of Gene Expression in Cancer. Clinical Chemistry, 2002, 48, 1170-1177.	1.5	132
259	Comparative genomic hybridization analysis of benign and invasive male breast neoplasms. Cancer Genetics and Cytogenetics, 2002, 134, 123-126.	1.0	8
260	Resolution of genotypic heterogeneity in prostate tumors using polymerase chain reaction and comparative genomic hybridization on microdissected carcinoma and prostatic intraepithelial neoplasia foci. Cancer Genetics and Cytogenetics, 2002, 137, 15-22.	1.0	24
261	Molecular cytogenetic analysis of head and neck squamous cell carcinoma: By comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head and Neck, 2002, 24, 874-887.	0.9	81
262	The role ofAlu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes and Cancer, 2002, 35, 97-112.	1.5	239
263	Identification of a novel gene NCRMS on chromosome 12q21 with differential expression between Rhabdomyosarcoma subtypes. Oncogene, 2002, 21, 3029-3037.	2.6	52
264	Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene, 2002, 21, 6480-6487.	2.6	44
265	Mutations in SUFU predispose to medulloblastoma. Nature Genetics, 2002, 31, 306-310.	9.4	722
266	Identification of Numerical Chromosomal Changes Detected by Interphase Fluorescence In Situ Hybridization in High-Grade Prostate Intraepithelial Neoplasia as a Predictor of Carcinoma. Archives of Pathology and Laboratory Medicine, 2002, 126, 165-169.	1.2	21
267	Genomic amplification in retinoblastoma narrowed to 0.6 megabase on chromosome 6p containing a kinesin-like gene, RBKIN. Cancer Research, 2002, 62, 967-71.	0.4	30
268	Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Research, 2002, 62, 3466-76.	0.4	96
269	Application of microarrays to the analysis of gene expression in cancer. Clinical Chemistry, 2002, 48, 1170-7.	1.5	38
270	Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. Cancer Research, 2002, 62, 6194-204.	0.4	38

#	Article	IF	Citations
271	Imprinting Status of 11p15 Genes in Beckwithâ€“Wiedemann Syndrome Patients with CDKN1C Mutations. Genomics, 2001, 74, 370-376.	1.3	55
272	Cloning and Characterization of the Human Retina-Specific Gene MPP4, a Novel Member of the p55 Subfamily of MAGUK Proteins. Genomics, 2001, 74, 377-384.	1.3	23
273	Evidence of Chromosomal Instability in Prostate Cancer Determined by Spectral Karyotyping (SKY) and Interphase FISH Analysis. Neoplasia, 2001, 3, 62-69.	2.3	49
274	Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood, 2001, 97, 3581-3588.	0.6	197
275	Advances in the detection of chromosomal aberrations using spectral karyotyping. Clinical Genetics, 2001, 59, 65-73.	1.0	58
276	Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer, 2001, 91, 2156-2164.	2.0	55
277	GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. American Journal of Medical Genetics Part A, 2001, 102, 161-168.	2.4	115
278	Comparative genomic hybridization detects novel amplifications in fibroadenomas of the breast. Genes Chromosomes and Cancer, 2001, 30, 25-31.	1.5	26
279	Molecular genetics of pineal region neoplasms. Journal of Neuro-Oncology, 2001, 54, 219-238.	1.4	18
280	Association of Alveolar Rhabdomyosarcoma with the Beckwith-Wiedemann Syndrome. Pediatric and Developmental Pathology, 2001, 4, 550-558.	0.5	53
281	Selection for transgene homozygosity in embryonic stem cells results in extensive loss of heterozygosity. Nature Genetics, 2001, 27, 257-258.	9.4	42
282	Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nature Genetics, 2001, 28, 220-221.	9.4	268
283	Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2001, 125, 87-99.	1.0	98
284	Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2001, 129, 57-63.	1.0	91
285	Comparative genomic hybridization analysis identifies gains of 1p35â^¼p36 and chromosome 19 in osteosarcoma. Cancer Genetics and Cytogenetics, 2001, 130, 14-21.	1.0	69
286	Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Human Molecular Genetics, 2001, 10, 2989-3000.	1.4	223
287	p53 Alteration and Chromosomal Instability in Prostatic High-Grade Intraepithelial Neoplasia and Concurrent Carcinoma: Analysis by Immunohistochemistry, Interphase In Situ Hybridization, and Sequencing of Laser-Captured Microdissected Specimens. Modern Pathology, 2001, 14, 1252-1262.	2.9	16
288	Molecular cytogenetic analysis of glial tumors using spectral karyotyping and comparative genomic hybridization. Molecular Diagnosis and Therapy, 2001, 6, 93-108.	1.3	16

#	Article	IF	Citations
289	Molecular Cytogenetic Analysis of Glial Tumors Using Spectral Karyotyping and Comparative Genomic Hybridization. Molecular Diagnosis and Therapy, 2001, 6, 93-108.	1.3	32
290	Comparative genomic hybridization analysis of clear cell sarcoma of the kidney. , 2000, 34, 113-116.		22
291	Chromosome 22q a frequent site of allele loss in head and neck carcinoma. Head and Neck, 2000, 22, 585-590.	0.9	14
292	Brca1 required for T cell lineage development but not TCR loci rearrangement. Nature Immunology, 2000, 1, 77-82.	7.0	74
293	Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia, 2000, 14, 1157-1160.	3.3	24
294	Comparative Genomic Hybridization Analysis Detects Frequent Over-Representation of DNA Sequences at 3q, 7p, and 8q in Head and Neck Carcinomas. Cancer Genetics and Cytogenetics, 2000, 119, 48-55.	1.0	51
295	Genetic Characterization of Immortalized Human Prostate Epithelial Cell Cultures. Cancer Genetics and Cytogenetics, 2000, 120, 50-57.	1.0	26
296	Use of Multicolor Spectral Karyotyping in Genetic Analysis of Pleuropulmonary Blastoma. Pediatric and Developmental Pathology, 2000, 3, 479-486.	0.5	19
297	Inactivation of 14-3-3Ï, Influences Telomere Behavior and Ionizing Radiation-Induced Chromosomal Instability. Molecular and Cellular Biology, 2000, 20, 7764-7772.	1.1	68
298	Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. Journal of Neurosurgery, 2000, 93, 437-448.	0.9	124
299	Alterations of H19 Imprinting and IGF2 Replication Timing Are Infrequent in Beckwithâ€“Wiedemann Syndrome. Genomics, 2000, 65, 234-242.	1.3	13
300	Spontaneous blastomere fusion after freezing and thawing of early human embryos leads to polyploidy and chromosomal mosaicism. Human Reproduction, 2000, 15, 2404-2410.	0.4	33
301	Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype. American Journal of Pathology, 2000, 157, 1623-1631.	1.9	287
302	Recurrent anomalies of 6q25 in chondromyxoid fibroma. Human Pathology, 2000, 31, 306-311.	1.1	67
303	Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by sequential Giemsa banding and spectral karyotyping. Molecular Diagnosis and Therapy, 2000, 5, 23-32.	1.3	9
304	Fusion of the ets Transcription Factor TEL to Jak2 Results in Constitutive Jak-Stat Signaling. Blood, 1999, 93, 4354-4364.	0.6	92
305	Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Therapy, 1999, 6, 482-497.	2.3	576
306	Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia, 1999, 13, 105-109.	3.3	35

#	Article	IF	Citations
307	Expression of WT1 in Pediatric Small Cell Tumors: Report of Two Cases with a Possible Mesothelial Origin. Pediatric and Developmental Pathology, 1999, 2, 33-41.	0.5	16
308	Variant EWS-WT1 Chimeric Product in the Desmoplastic Small Round Cell Tumor. Pediatric and Developmental Pathology, 1999, 2, 188-192.	0.5	31
309	Hemangioendothelioma of Bone in a Patient with a Constitutional Supernumerary Marker. Cancer Genetics and Cytogenetics, 1999, 110, 23-27.	1.0	16
310	Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-Î±. Experimental Hematology, 1999, 27, 1176-1184.	0.2	49
311	Sequential G-banding, SKY and FISH provide a refined identification of translocation breakpoints and complex chromosomal rearrangements. Technical Tips Online, 1999, 4, 66-69.	0.2	3
312	Identification of a novel zinc finger gene,zf5-3, as a potential mediator of neuroblastoma differentiation. , 1999, 81, 970-978.		8
313	Application of Comparative Genomic Hybridization, Spectral Karyotyping, and Microarray Analysis in the Identification of Subtype-Specific Patterns of Genomic Changes in Rhabdomyosarcoma. Neoplasia, 1999, 1, 262-275.	2.3	76
314	Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization. Pathology, 1999, 31, 337-344.	0.3	34
315	Analysis of Genomic Integrity and p53-Dependent G₁Checkpoint in Telomerase-Induced Extended-Life-Span Human Fibroblasts. Molecular and Cellular Biology, 1999, 19, 2373-2379.	1.1	100
316	Familial Evans Syndrome. Journal of Pediatric Hematology/Oncology, 1999, 21, 244-247.	0.3	14
317	Analysis of Chromosome 22q as an Aid to the Diagnosis of Rhabdoid Tumor. American Journal of Surgical Pathology, 1999, 23, 982.	2.1	19
318	Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Research, 1999, 59, 1731s-1735s.	0.4	98
319	Molecular Genetics in the Diagnosis and Prognosis of Solid Pediatric Tumors. Pediatric and Developmental Pathology, 1998, 1, 337-365.	0.5	23
320	Malignant myeloid transformation with isochromosome 7q in Shwachmanâ€“Diamond syndrome. Leukemia, 1998, 12, 1591-1595.	3.3	63
321	Molecular genetics of Wiedemann-Beckwith syndrome. , 1998, 79, 253-259.		135
322	Melanotic Neuroectodermal Tumor of Infancy: A Molecular Genetic Study. Pediatric and Developmental Pathology, 1998, 1, 295-299.	0.5	44
323	Structural Characterization and Mapping of the Normal Epithelial Cell-Specific 1 Gene. Biochemical and Biophysical Research Communications, 1998, 247, 580-586.	1.0	48
324	Molecular Genetic Changes in Alveolar Soft Part Sarcoma. Fetal and Pediatric Pathology, 1998, 18, 529-543.	0.3	0

#	Article	IF	Citations
325	Role of New Cytogenetic Methodologies in the Management of Acute Myeloid Leukemia. Leukemia and Lymphoma, 1998, 30, 37-37.	0.6	0
326	Molecular Genetic Changes in Alveolar Soft Part Sarcoma. Fetal and Pediatric Pathology, 1998, 18, 529-543.	0.4	1
327	Heterogeneity ofMYCNAmplification in a Child with Stroma-Rich Neuroblastoma (Ganglioneuroblastoma). Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 875-883.	0.3	13
328	Molecular genetics of Beckwith-Wiedemann syndrome. Current Opinion in Pediatrics, 1997, 9, 623-629.	1.0	52
329	Loss of Imprinting of Human Insulin-like Growth Factor II Gene, IGF2, in Acute Myeloid Leukemia. Biochemical and Biophysical Research Communications, 1997, 231, 466-472.	1.0	57
330	Promoter-Dependent Tissue-Specific Expressive Nature of Imprinting Gene, Insulin-like Growth Factor II, in Human Tissues. Biochemical and Biophysical Research Communications, 1997, 233, 221-226.	1.0	31
331	Relaxation of Imprinting of Human Insulin-like Growth Factor II Gene,IGF2,in Sporadic Breast Carcinomas. Biochemical and Biophysical Research Communications, 1997, 235, 123-129.	1.0	52
332	Mapping of the Gene Encoding the Integrin-Linked Kinase, ILK, to Human Chromosome 11p15.5â€“p15.4. Genomics, 1997, 42, 177-179.	1.3	38
333	Chromosomal Mapping of the Human and Murine Orphan Receptors ERRÎ± (ESRRA) and ERRÎ² (ESRRB) and Identification of a Novel Human ERRÎ±-Related Pseudogene. Genomics, 1997, 45, 320-326.	1.3	33
334	Intracranial and spinal metastases from a ganglioglioma with unusual cytogenetic abnormalities in a patient with complex partial seizures. Child's Nervous System, 1997, 13, 550-555.	0.6	27
335	Relational mapping ofMYCN andDDX1 in band 2p24 and analysis of amplicon arrays in double minute chromosomes and homogeneously staining regions by use of free chromatin FISH. , 1997, 20, 243-252.		22
336	HETEROGENEITY OF MYCN AMPLIFICATION IN A CHILD WITH STROMA-RICH NEUROBLASTOMA (GANGLIONEUROBLASTOMA). Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 875-884.	0.3	9
337	Heterogeneity of MYCN Amplification in a Child with Stroma-Rich Neuroblastoma (Ganglioneuroblastoma). Fetal and Pediatric Pathology, 1997, 17, 875-883.	0.4	1
338	Introduction: Genetic rearrangements in cancer. Seminars in Cancer Biology, 1996, 7, 1.	4.3	0
339	Clinical applications of genetic rearrangements in cancer. Seminars in Cancer Biology, 1996, 7, 25-32.	4.3	11
340	Genomic imprinting in tumours. Seminars in Cancer Biology, 1996, 7, 41-47.	4.3	14
341	Selection of probes for fluorescence in situ hybridization analysis by differential display polymerase chain reaction of mRNA from rhabdomyosarcoma. Cancer Genetics and Cytogenetics, 1996, 92, 58-65.	1.0	4
342	Molecular biology of Beckwith-Wiedemann syndrome. , 1996, 27, 462-469.		55

#	Article	IF	Citations
343	Juvenile Chronic Myelogenous Leukemia Multilineage CD34+Cells: Aberrant Growth and Differentiation Properties. Stem Cells, 1996, 14, 690-701.	1.4	13
344	Glypicans: a growing trend. Nature Genetics, 1996, 12, 225-227.	9.4	74
345	Allelic fusion of DNA topoisomerase IIα and retinoic acid receptor α genes in Adriamycin-resistant p388 murine leukemia revealed by fluorescence in situ hybridization. Cytogenetic and Genome Research, 1996, 75, 164-166.	0.6	1
346	Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types. American Journal of Pathology, 1996, 148, 1125-38.	1.9	85
347	Identification of MYCN Copy Number Heterogeneity by Direct FISH Analysis of Neuroblastoma Preparations. Molecular Diagnosis and Therapy, 1996, 1, 281-289.	1.3	15
348	Molecular and Cytogenetic Analysis of a Cerebellar Primitive Neuroectodermal Tumor with Prominent Neuronal Differentiation: Detection of MYCN Amplification by Differential Polymerase Chain Reaction and Southern Blot Analysis. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1995, 15, 733-744.	0.3	16
349	Mitochondrial ATP synthase Î±-subunit gene amplified in a retinoblastoma cell line maps to chromosome 18. Genes Chromosomes and Cancer, 1995, 14, 63-67.	1.5	6
350	Mapping of the gonadotropin-releasing hormone (GnRH) receptor gene to human Chromosome 4q21.2 by fluorescence in situ hybridization. Mammalian Genome, 1995, 6, 309-310.	1.0	10
351	Application of a Simplified Comparative Genomic Hybridization Technique to Screen for Gene Amplification in Pediatric Solid Tumors. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1995, 15, 831-844.	0.3	18
352	Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics, 1995, 26, 138-141.	1.3	81
353	The Orphan Nuclear Receptor RORÎ± (RORA) Maps to a Conserved Region of Homology on Human Chromosome 15q21-q22 and Mouse Chromosome 9. Genomics, 1995, 28, 596-598.	1.3	39
354	The human UDPâ€‹Nâ€‹Acetylglucosamine:Î±â€‹6â€‹<scp>d</scp>â€‹Mannosideâ€‹Î²â€‹1,2â€‹Nâ€‹Acetylglucosaminyltransferase II Gene (MGAT2). FEBS Journal, 1995, 231, 317-328.	1.2	8
355	The human UDP-N-Acetylglucosamine:alpha-6-d-Mannoside-beta-1,2-N-Acetylglucosaminyltransferase II Gene (MGAT2). Cloning of Genomic DNA, Localization to Chromosome 14q21, Expression in Insect Cells and Purification of the Recombinant Protein. FEBS Journal, 1995, 231, 317-328.	0.2	78
356	Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene, 1995, 10, 1417-22.	2.6	80
357	A heat shock gene at 14q22: mapping and expression. Human Molecular Genetics, 1994, 3, 1819-1822.	1.4	19
358	Assessment ofMycnAmplification in Neuroblastoma Biopsies by Differential Polymerase Chain Reaction. Pediatric Pathology, 1994, 14, 823-832.	0.5	25
359	Pediatric malignant glioma with tubuloreticular inclusions and MYCN amplification. Report of a case with immunohistochemical, ultrastructural, flow cytometric, karyotypic, and southern blot analysis. Cancer, 1994, 73, 1987-1993.	2.0	7
360	MYCN gene amplification in rhabdomyosarcoma. Cancer, 1994, 73, 2231-2237.	2.0	94

#	Article	IF	Citations
361	Malignant transformation in a ganglioglioma with anaplastic neuronal and astrocytic components. Report of a case with flow cytometric and cytogenetic analysis. Cancer, 1994, 73, 2862-2868.	2.0	102
362	Localization of beckwith-wiedemann and rhabdoid tumor chromosome rearrangements to a defined interval in chromosome band 11p15.5. Genes Chromosomes and Cancer, 1994, 11, 97-105.	1.5	42
363	Characterization of human hepatocyte lines derived from normal liver tissue. Hepatology, 1994, 19, 1390-1399.	3.6	66
364	Localization of the Interferon-Induced, 2-5A-Dependent RNase Gene (RNS4) to Human Chromosome 1q25. Genomics, 1994, 19, 174-175.	1.3	25
365	Assignment of the Human Prostaglandin-Endoperoxide Synthase 2 (PTGS2) Gene to 1q25 by Fluorescence in Situ Hybridization. Genomics, 1994, 23, 718-719.	1.3	46
366	A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukemia, 1994, 8, 236-44.	3.3	54
367	Variant translocations of chromosome 22 in Ewing's sarcoma. Genes Chromosomes and Cancer, 1993, 8, 190-194.	1.5	29
368	Disruption of insulinâ€“like growth factor 2 imprinting in Beckwithâ€“Wiedemann syndrome. Nature Genetics, 1993, 5, 143-150.	9.4	423
369	Localization of the Human Interferon-Induced, ds-RNA Activated p68 Kinase Gene (PRKR) to Chromosome 2p21-p22. Genomics, 1993, 16, 768-770.	1.3	24
370	Astroblastoma: Report of a Case with Ultrastructural, Cell Kinetic, and Cytogenetic Analysis. Pediatric Pathology, 1993, 13, 323-332.	0.5	40
371	Characterization of abnormal one pronuclear human oocytes by morphology, cytogenetics and in-situ hybridization. Human Reproduction, 1993, 8, 402-408.	0.4	43
372	Amplification of a DEAD box protein gene in retinoblastoma cell lines.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7578-7582.	3.3	92
373	Mechanisms of loss of heterozygosity in retinoblastoma. Cytogenetic and Genome Research, 1992, 59, 248-252.	0.6	93
374	High-resolution mapping of mammalian genes by in situ hybridization to free chromatin.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9509-9513.	3.3	515
375	Molecular genetic, cytogenetic, and immunohistochemical characterization of alveolar soft-part sarcoma: Implications for cell of origin. Cancer, 1992, 70, 2444-2450.	2.0	57
376	Infrequent genomic rearrangement and normal expression of the putative RB1 gene in retinoblastoma tumors.. Molecular and Cellular Biology, 1988, 8, 2082-2088.	1.1	75
377	Re-evaluation of the sublocalization of esterase D and its relation to the retinoblastoma locus by in situ hybridization. Cytogenetic and Genome Research, 1987, 44, 153-157.	0.6	25
378	Genetic origin of mutations predisposing to retinoblastoma. Survey of Ophthalmology, 1986, 31, 141-142.	1.7	0

#	Article	IF	Citations
379	Cloning of the esterase D gene: a polymorphic gene probe closely linked to the retinoblastoma locus on chromosome 13.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 6573-6577.	3.3	65
380	Tumour induction by the retinoblastoma mutation is independent of N-myc expression. Nature, 1986, 322, 555-557.	13.7	76
381	A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma. Human Genetics, 1985, 70, 291-301.	1.8	126
382	Genetic origin of mutations predisposing to retinoblastoma. Science, 1985, 228, 501-503.	6.0	355
383	Isochromosome 6p, a unique chromosomal abnormality in retinoblastoma: Verification by standard staining techniques, new densitometric methods, and somatic cell hybridization. Human Genetics, 1984, 66, 46-53.	1.8	90
384	Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature, 1983, 304, 451-453.	13.7	227
385	Prenatal diagnosis and outcome of pregnancy in 2036 women investigated by amniocentesis. Human Genetics, 1982, 61, 215-222.	1.8	24
386	Mining Extracellular Vesicles for Clinically Relevant Noninvasive Diagnostic Biomarkers in Cancer. , 0, , .		1